We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+12.38%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$4.12B
AUM Growth
+$545M
Cap. Flow
+$53M
Cap. Flow %
1.29%
Top 10 Hldgs %
48.24%
Holding
158
New
26
Increased
23
Reduced
71
Closed
24

Top Buys

Rank Stock Value
1
KLRS
Kalaris Therapeutics
KLRS
+$69M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$68.4M
3
BEKE icon
KE Holdings
BEKE
+$43.5M
4
IGMS
IGM Biosciences
IGMS
+$40.8M
5
ITOS
iTeos Therapeutics
ITOS
+$29.4M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$42.9M
2
PYPL icon
PayPal
PYPL
+$34.8M
3
AVTR icon
Avantor
AVTR
+$34M
4
ARGX icon
argenx
ARGX
+$30.2M
5
Z icon
Zillow
Z
+$22.1M

Sector Composition

Rank Sector Weight
1 Healthcare 57.99%
2 Miscellaneous 26.49%
3 Consumer Discretionary 10.25%
4 Technology 2.5%
5 Real Estate 1.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXDX
101
DELISTED
Accelerate Diagnostics
AXDX
$4.56M 0.11%
42,750
-15,900
-27% -$2.21M
SYRS
102
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$4.12M 0.1%
46,550
-2,450
-5% -$278K
YI
103
111 Inc
YI
$31.6M
$4.03M 0.1%
65,000
– –
RNAM
104
DELISTED
Avidity Biosciences
RNAM
$4.01M 0.1%
142,500
-32,500
-19% -$939K
NTLA icon
105
Intellia Therapeutics
NTLA
$1.66B
$3.78M 0.09%
190,000
-49,000
-21% -$1.02M
ALXO icon
106
ALX Oncology
ALXO
$268M
$3.77M 0.09%
+100,000
New +$3.93M
OXY icon
107
Occidental Petroleum
OXY
$61.8B
$3.75M 0.09%
+375,000
New +$5.29M
ORIC icon
108
Oric Pharmaceuticals
ORIC
$1.25B
$3.56M 0.09%
142,500
-7,500
-5% -$179K
PRTA icon
109
Prothena Corp
PRTA
$458M
$3.51M 0.09%
351,500
-18,500
-5% -$223K
SLDB icon
110
Solid Biosciences
SLDB
$933M
$3.47M 0.08%
114,000
-6,000
-5% -$230K
AUTL
111
Autolus Therapeutics
AUTL
$516M
$3.32M 0.08%
285,000
-115,000
-29% -$1.67M
AXLA
112
DELISTED
Axcella Health Inc. Common Stock
AXLA
$3.29M 0.08%
28,500
-7,500
-21% -$924K
ADCT icon
113
ADC Therapeutics
ADCT
$137M
$3.13M 0.08%
95,000
-41,000
-30% -$1.77M
PRVL
114
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$3.08M 0.07%
302,750
-67,250
-18% -$902K
MRUS
115
DELISTED
Merus
MRUS
$3M 0.07%
250,000
-134,000
-35% -$1.73M
ZNTL icon
116
Zentalis Pharmaceuticals
ZNTL
$332M
$2.86M 0.07%
87,400
-4,600
-5% -$161K
PTGX icon
117
Protagonist Therapeutics
PTGX
$9.56B
$2.6M 0.06%
133,000
-7,000
-5% -$131K
EVLO
118
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$2.5M 0.06%
23,750
-9,583
-29% -$873K
NERV icon
119
Minerva Neurosciences
NERV
$198M
$2.42M 0.06%
95,000
-5,000
-5% -$135K
LITS
120
Lite Strategy Inc
LITS
$37.8M
$2.37M 0.06%
38,000
+2,300
+6% +$139K
KDNY
121
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$2.19M 0.05%
180,500
-9,500
-5% -$127K
PAND
122
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
$1.66M 0.04%
+145,000
New +$2.48M
CRIS icon
123
Curis
CRIS
$2.72M
$1.64M 0.04%
3,512
-185
-5% -$87.3K
CHMA
124
DELISTED
Chiasma, Inc. Common Stock
CHMA
$1.63M 0.04%
+380,000
New +$1.82M
ACET icon
125
Adicet Bio
ACET
$89.1M
$1.54M 0.04%
8,083
-426
-5% -$108K
3 4
5
6 7

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q3 2020 Portfolio in Review

As of Q3 2020, Artal Group held 158 positions worth $4.12B, up 15% from $3.57B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Artal Group's Q3 2020 filing shows 26 new, 23 increased, 71 reduced and 24 closed positions. Its largest new stake was Kalaris Therapeutics: 101,016 shares worth $63.9M. The largest sale was Blueprint Medicines, an estimated $42.9M.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, down from 62% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.

  • Artal Group's largest Q3 2020 buy was Kalaris Therapeutics: 101,016 shares worth $63.9M.
  • Artal Group added most to Agenus in Q3 2020, an estimated $16.1M increase.
  • Artal Group's biggest Q3 2020 reduction was argenx, cutting an estimated $30.2M.
  • Artal Group fully exited Blueprint Medicines in Q3 2020, selling an estimated $42.9M.
  • Artal Group's ten largest holdings make up 48% of its $4.12B portfolio in Q3 2020.
  • Artal Group opened 26 new positions and closed 24 in Q3 2020.
  • Artal Group's portfolio value rose 15% quarter-over-quarter to $4.12B.

Based on Artal Group's 13F filing for Q3 2020, filed 13 Nov 2020.